Shandong Xinhua Pharmaceutical Company   Report issue

For profit Phase 2
Founded: Shandong China (1943)
Status: No NME R&D (1943)

Organization Overview

First Clinical Trial
2007
NCT00544518
First Marketed Drug
2016
ibuprofen (motrin)
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

SHANDONG XINHUA

Active Ingredients

Marketed Drugs (1)

ibuprofen (motrin) (2016)

Drugs in Phase 2 Trials (2)

benfluorex (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2